0

Inflammatory Bowel Disease Collection
 1-20 of 120 Articles
Editorials |  20 May 2014
Which Biological Agents Are Most Appropriate for Ulcerative Colitis?Which Biological Agents Are Most Appropriate for Ulcerative Colitis?
Ole Haagen Nielsen, MD, DMSc; Mark Andrew Ainsworth, MD, PhD, DMSc
Ann Intern Med. 2014;160(10):733-734. doi:10.7326/M14-0605
Reviews |  20 May 2014
Biological Agents for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Network Meta-analysisBiological Agents for Ulcerative Colitis
Silvio Danese, MD, PhD; Gionata Fiorino, MD, PhD; Laurent Peyrin-Biroulet, MD, PhD; et al.
Ann Intern Med. 2014;160(10):704-711. doi:10.7326/M13-2403
Original Research |  6 March 2012
Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study
Ashwin N. Ananthakrishnan, MD, MPH; Leslie M. Higuchi, MD, MPH; Edward S. Huang, MD, MPH; et al.
Ann Intern Med. 2012;156(5):350-359. doi:10.7326/0003-4819-156-5-201203060-00007
Articles |  6 November 2007
Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis: A Randomized Trial
Wolfgang Stremmel, MD; Robert Ehehalt, MD; Frank Autschbach, MD; et al.
Ann Intern Med. 2007;147(9):603-610. doi:10.7326/0003-4819-147-9-200711060-00004
Editorials |  19 June 2007 FREE
GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease
Peter Mannon, MD
Ann Intern Med. 2007;146(12):888-890. doi:10.7326/0003-4819-146-12-200706190-00011
Articles |  19 June 2007 FREE
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial
William J. Sandborn, MD; Paul Rutgeerts, MD, PhD; Robert Enns, MD; et al.
Ann Intern Med. 2007;146(12):829-838. doi:10.7326/0003-4819-146-12-200706190-00159
Reviews |  20 December 2005
New Concepts in the Pathophysiology of Inflammatory Bowel Disease
Giorgos Bamias, MD; Mark R. Nyce, MD; Sarah A. De La Rue, PhD; et al.
Ann Intern Med. 2005;143(12):895-904. doi:10.7326/0003-4819-143-12-200512200-00007
Therapeutics |  May/Jun 2002
Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease
Gurinder Luthra, MD; P. Jay Pasricha, MD
Ann Intern Med. 2002;136(3):92. doi:10.7326/ACPJC-2002-136-3-092
Brief Communications |  15 January 2002
Reporting on Statistical Methods To Adjust for Confounding: A Cross-Sectional Survey
Marcus Müllner, MD; Hugh Matthews, BSc, MBBS; Douglas G. Altman, DSc
Ann Intern Med. 2002;136(2):122-126. doi:10.7326/0003-4819-136-2-200201150-00009
Reviews |  20 November 2001
Diagnosis and Treatment of Perianal Fistulas in Crohn Disease
David A. Schwartz, MD; John H. Pemberton, MD; William J. Sandborn, MD
Ann Intern Med. 2001;135(10):906-918. doi:10.7326/0003-4819-135-10-200111200-00011
Reviews |  21 August 2001
Migration of T Cells in Vivo: Molecular Mechanisms and Clinical Implications
Jürgen Westermann, MD; Britta Engelhardt, MD; Jörg C. Hoffmann, MD
Ann Intern Med. 2001;135(4):279-295. doi:10.7326/0003-4819-135-4-200108210-00013
Academia and the Profession |  19 June 2001
Methodologic Pitfalls in the Determination of Genetic Anticipation: The Case of Crohn Disease
Michael F. Picco, MD, PhD; Steven Goodman, MD, PhD; James Reed, PhD; et al.
Ann Intern Med. 2001;134(12):1124-1129. doi:10.7326/0003-4819-134-12-200106190-00013
Editorials |  16 January 2001 FREE
Chemoprevention in Ulcerative Colitis: Narrowing the Gap between Clinical Practice and Research
Ernest T. Hawk, MD, MPH; Jaye L. Viner, MD, MA
Ann Intern Med. 2001;134(2):158-160. doi:10.7326/0003-4819-134-2-200101160-00017
Articles |  16 January 2001
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
Bruce Y. Tung, MD; Mary J. Emond, PhD; Rodger C. Haggitt, MD; et al.
Ann Intern Med. 2001;134(2):89-95. doi:10.7326/0003-4819-134-2-200101160-00008
Brief Communications |  21 November 2000
The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study
Charles N. Bernstein, MD; James F. Blanchard, MD, PhD; William Leslie, MD; et al.
Ann Intern Med. 2000;133(10):795-799. doi:10.7326/0003-4819-133-10-200011210-00012
Brief Communications |  15 May 1997
Intravenous Iron and Erythropoietin for Anemia Associated with Crohn Disease: A Randomized, Controlled Trial
Christoph Gasche, MD; Clemens Dejaco, MD; Thomas Waldhoer, PhD; et al.
Ann Intern Med. 1997;126(10):782-787. doi:10.7326/0003-4819-126-10-199705150-00006
Articles |  1 March 1997
Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial
William J. Sandborn, MD; William J. Tremaine, MD; Kenneth P. Offord, MS; et al.
Ann Intern Med. 1997;126(5):364-371. doi:10.7326/0003-4819-126-5-199703010-00004
Articles |  15 January 1996
An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis: A Randomized, Placebo-Controlled Trial
Stephen B. Hanauer, MD; Charles A. Sninsky, MD; Malcom Robinson, MD; et al.
Ann Intern Med. 1996;124(2):204-211. doi:10.7326/0003-4819-124-2-199601150-00003
Reviews |  15 July 1995
Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
David C. Pearson; Gary R. May; Gordon H. Fick; et al.
Ann Intern Med. 1995;123(2):132-142. doi:10.7326/0003-4819-123-2-199507150-00009
Reviews |  1 November 1994
The Role of Leukotrienes in Inflammation
William R. Henderson, MD
Ann Intern Med. 1994;121(9):684-697. doi:10.7326/0003-4819-121-9-199411010-00010
Advertisement

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)